Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety
of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients
with extensive stage small-cell lung cancer.